October 3, 2024- McKesson Corporation announced the launch of InspiroGeneTM by McKesson (“InspiroGene”), a dedicated business focused solely on supporting the commercialization of cell and gene therapies (CGTs). With a scalable, flexible suite of services and an experienced leadership team, InspiroGene enables manufacturers, payers, and providers to navigate the complex CGT commercialization landscape to ensure patients can access the life-changing treatments they need.
InspiroGene brings unparalleled experience in every stage of the CGT life cycle and has established the following solutions to address the complex challenges of bringing CGTs to market:
- Third-party logistics (3PL) programs that meet the unique demands of CGT manufacturers, with financial management solutions, logistics, and cutting-edge data analytics to provide seamless operations for CGTs.
- Specialty distribution services that leverage McKesson’s extensive supply chain network, offering high-touch logistics and advanced data analytics to ensure CGTs reach patients efficiently and effectively.
- Biologics specialty pharmacy solutions dedicated to CGTs, including precision dispensing to expedite time to treatment, and patient management services to efficiently address the unique needs of patients based on therapy type.
- CGT dedicated patient hub that provides tailored access and support services for patients, as well as operational case management for providers, patients, and caregivers.